Breaking News
55 minutes ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Plus Therapeutics' CNSide Diagnostics secures Medicare PTAN, enabling claims submission for its CSF tumor cell enumeration test pending MAC coverage determinations.
Pharma Now Editorial Team

FDA tentatively approves PNT2003 as the first radioequivalent for Lu 177 Dotatate, setting a GMP and regulatory benchmark for radiopharmaceutical generics.
Pharma Now Editorial Team
Aclaris ATI-052 Phase 1a data confirm 45-day half-life and quarterly dosing potential, with Phase 2b in asthma targeted for Q4 2026.
Pharma Now Editorial Team

EMA, MHRA, and Swissmedic decisions on obicetrapib expected H2 2026, with Menarini targeting Q4 launches in Germany and the UK.
Pharma Now Editorial Team
